<SEC-DOCUMENT>0001628280-22-029592.txt : 20221114
<SEC-HEADER>0001628280-22-029592.hdr.sgml : 20221114
<ACCEPTANCE-DATETIME>20221114061028
ACCESSION NUMBER:		0001628280-22-029592
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221114
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221114
DATE AS OF CHANGE:		20221114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKWELL MEDICAL, INC.
		CENTRAL INDEX KEY:			0001041024
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				383317208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23661
		FILM NUMBER:		221379645

	BUSINESS ADDRESS:	
		STREET 1:		30142 WIXOM ROAD
		CITY:			WIXOM
		STATE:			MI
		ZIP:			48393
		BUSINESS PHONE:		8004493353

	MAIL ADDRESS:	
		STREET 1:		30142 WIXOM ROAD
		CITY:			WIXOM
		STATE:			MI
		ZIP:			48393

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20120530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL, INC.
		DATE OF NAME CHANGE:	20120525

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19970722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rmti-20221114.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:e88dabdf-1e2f-48bb-b177-efab24ab0ca7,g:91dfe646-35bd-407a-a5c7-cb47f94d99a2,d:3a17a6b32be64c34a08aa578f76adc44--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rmti-20221114</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF80L2ZyYWc6NDAyMzAwZTgwYWUzNGMwZjllYzViZGQ0MDMyZTY5ZDEvdGFibGU6NDg3MzM2ZTY2YjI0NGJlZGI3MWNhODBhZDNjYmVjYjAvdGFibGVyYW5nZTo0ODczMzZlNjZiMjQ0YmVkYjcxY2E4MGFkM2NiZWNiMF8xLTEtMS0xLTQ4NDU4_122f734c-4cfc-4ab2-87ba-8458134a1acd">0001041024</ix:nonNumeric><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF80L2ZyYWc6NDAyMzAwZTgwYWUzNGMwZjllYzViZGQ0MDMyZTY5ZDEvdGFibGU6NDg3MzM2ZTY2YjI0NGJlZGI3MWNhODBhZDNjYmVjYjAvdGFibGVyYW5nZTo0ODczMzZlNjZiMjQ0YmVkYjcxY2E4MGFkM2NiZWNiMF8yLTEtMS0xLTQ4NDU4_25614b7e-4da3-4486-b88a-6564a11a62dd">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rmti-20221114.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-14</xbrli:startDate><xbrli:endDate>2022-11-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i3a17a6b32be64c34a08aa578f76adc44_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNTAz_0b4c65e5-3aaa-4946-8de5-7ca763f005d6">8-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yMzU_4082c4e9-3c10-49a3-a068-3032b2c37164">November 14, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNTAw_808195a7-eafe-45a1-8149-e0ce361fc4b4">ROCKWELL MEDICAL,&#160;INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:31.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6M2ZlMDQwMTEzZDM3NGYxYzgwMGU1ZTI5ZTNlZWViZTMvdGFibGVyYW5nZTozZmUwNDAxMTNkMzc0ZjFjODAwZTVlMjllM2VlZWJlM18wLTAtMS0xLTQ4NDU4_a8b6430d-1a06-40b3-b697-6725f63b4b9e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6M2ZlMDQwMTEzZDM3NGYxYzgwMGU1ZTI5ZTNlZWViZTMvdGFibGVyYW5nZTozZmUwNDAxMTNkMzc0ZjFjODAwZTVlMjllM2VlZWJlM18wLTEtMS0xLTQ4NDU4_b8b8304b-26bf-458d-886a-9bb340e26d9f">000-23661</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6M2ZlMDQwMTEzZDM3NGYxYzgwMGU1ZTI5ZTNlZWViZTMvdGFibGVyYW5nZTozZmUwNDAxMTNkMzc0ZjFjODAwZTVlMjllM2VlZWJlM18wLTItMS0xLTQ4NDU4_1c765c1f-be6a-4181-b1cc-d1b360cda391">38-3317208</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction<br/>of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNTA1_5b76aa98-1808-4ca6-a433-5ff0cbda9aff">30142 S. Wixom Road</ix:nonNumeric>, <ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNTAx_a4207dee-b267-4971-8f98-ebea5fa8db29">Wixom</ix:nonNumeric>, <ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNTA2_82f06f42-ceda-42ce-937c-8dbab0522677">Michigan</ix:nonNumeric> <ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNDk2_f0dd9779-bbf6-4943-b376-cfe5abeac9d6">48393</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNDk3_94d47264-98db-45c7-a657-c1098d8681dd">248</ix:nonNumeric>) <ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNDk4_53671f39-3a31-4808-b722-1a1f393d8a1b">960-9009</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:454.50pt"><tr><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:427.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6Y2Q4ZTFiYjNjNjFhNGY3MzliNDczYjE1MmMzMWRhZGQvdGFibGVyYW5nZTpjZDhlMWJiM2M2MWE0ZjczOWI0NzNiMTUyYzMxZGFkZF8wLTEtMS0xLTQ4NDU4_f7709ec4-5afc-427b-82c6-ab8340e70c36">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:454.50pt"><tr><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:427.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6ODk3MjVlMjViNTYwNGExMDk1NTI2ZDFiNWY4ZjQyNWIvdGFibGVyYW5nZTo4OTcyNWUyNWI1NjA0YTEwOTU1MjZkMWI1ZjhmNDI1Yl8wLTEtMS0xLTQ4NDU4_5ffa2d67-e119-4c64-800f-9d4f5c1fcc57">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:484.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6YzhiZWM2ODM1YTkzNGE3ZTgyMTM3Njk1YTc0MjJmMTYvdGFibGVyYW5nZTpjOGJlYzY4MzVhOTM0YTdlODIxMzc2OTVhNzQyMmYxNl8wLTEtMS0xLTQ4NDU4_16a1b10c-51cd-46b8-8b8f-6edd8b61c9a0">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:7.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:484.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6MmMyMDA1Mjc0Nzk2NDQwMThmN2EyYWU0MDQwYmQ4NTcvdGFibGVyYW5nZToyYzIwMDUyNzQ3OTY0NDAxOGY3YTJhZTQwNDBiZDg1N18wLTEtMS0xLTQ4NDU4_2fa11c2c-cdc3-4db2-9d91-0a9aff7cb0e1">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title&#160;of&#160;Each&#160;Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading&#160;Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name&#160;of&#160;Each&#160;exchange&#160;on&#160;which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6MWU0YTc4ZWE4OGZmNGQ4MTliYjI4Y2MxM2NjZWQ4NDAvdGFibGVyYW5nZToxZTRhNzhlYTg4ZmY0ZDgxOWJiMjhjYzEzY2NlZDg0MF8xLTAtMS0xLTQ4NDU4_c543c355-eeb9-4e9a-8172-cd901ae91f99">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6MWU0YTc4ZWE4OGZmNGQ4MTliYjI4Y2MxM2NjZWQ4NDAvdGFibGVyYW5nZToxZTRhNzhlYTg4ZmY0ZDgxOWJiMjhjYzEzY2NlZDg0MF8xLTItMS0xLTQ4NDU4_c0b4019b-5feb-405f-b3dd-cdd1e2e1399f">RMTI</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6MWU0YTc4ZWE4OGZmNGQ4MTliYjI4Y2MxM2NjZWQ4NDAvdGFibGVyYW5nZToxZTRhNzhlYTg4ZmY0ZDgxOWJiMjhjYzEzY2NlZDg0MF8xLTQtMS0xLTQ4NDU4L3RleHRyZWdpb246YzU5NmQwYTdhNThjNGE0NWIzYzYxNzU5NzE2OWEyOTFfNA_4127c66e-198b-44cd-936c-dbe186ac4177">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNTAy_6868fbe9-a34a-4d04-8dfd-d17cec2c83a3">&#9744;</ix:nonNumeric> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Item&#160;2.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 14, 2022, Rockwell Medical, Inc. issued a press release and earnings presentation announcing its financial results for the quarter ended September 30, 2022. The press release and earnings presentation are furnished as Exhibit 99.1 to this Current Report on Form 8&#8209;K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 incorporated in this Form 8-K shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Item&#160;9.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Financial Statements and Exhibits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;Exhibits&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The following exhibit is being furnished herewith:</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT&#160;INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.228%"><tr><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.081%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rmtiq32022earningspr-final.htm">Press Release, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rmtiq32022earningspr-final.htm">November 14</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="rmtiq32022earningspr-final.htm">, 2022</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in INline XBRL and included as Exhibit 101.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.261%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROCKWELL MEDICAL,&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: Novermber 14, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Mark Strobeck</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Strobeck</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rmtiq32022earningspr-final.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if7d84abbe1584107a8774421726becaa_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:115%">Rockwell Medical Provides Business Strategy Update and Announces Third Quarter 2022 Financial and Operational Results </font></div><div><font><br></font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">Rockwell is restructuring its business in the short-term to drive revenue and expansion opportunities in the growing hemodialysis market and through international pharmaceutical sales  </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">By making this strategic shift, Rockwell expects to achieve profitability in 2024, strengthen its overall financial position, and reduce the Company&#8217;s reliance on the capital markets to fund future business growth</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">Rockwell amended its long-term debt agreement to align with its updated strategic direction&#59; Reduced debt from $15 million to $10 million</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">Revenue was $18.7 million for the third quarter 2022, which represents the highest quarterly revenue to-date for Rockwell</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.8pt">Cash used in operating activities was $1.1 million for the third quarter 2022, an 81% decrease over the second quarter 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Wixom, Michigan, November 14, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> &#8211; Rockwell Medical, Inc. (&#8220;Rockwell&#8221; or the &#8220;Company&#8221;) (Nasdaq&#58; RMTI), a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney, today provided an update on its overall business strategy and announced its financial and operational results for the third quarter ended September 30, 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BUSINESS STRATEGY UPDATE</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the third quarter of 2022, Rockwell Medical evaluated its businesses and the potential for short- and long-term value. Going forward, Rockwell will focus its efforts on growing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the Company&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> revenue-generating businesses, which currently include its hemodialysis concentrates business and international partnerships for TRIFERIC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, pausing further investment in capital-intensive pharmaceutical development programs, and achieving profitability to put the Company in a stronger and more stable financial position</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As a result of these efforts, Rockwell </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">expects to achieve profitability in 2024. Once the Company achieves profitability and sustains cash flow from its revenue-generating businesses, it will then consider investments in higher value, longer-term products to develop a broader kidney care products portfolio. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subsequent to the third quarter of 2022, Rockwell announced that it is reacquiring its distribution rights to its hemodialysis concentrates products from Baxter and has agreed to terminate the exclusive distribution agreement dated October 2, 2014.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rockwell will acquire more than 700 hemodialysis concentrates customers including hospitals, medical centers, dialysis centers, and health systems, and will begin selling directly to new customers throughout the United States and internationally.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With Rockwell&#8217;s current customers and projected growth, the Company believes that it will be able to achieve $100 million in revenue annually in the next few years. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furthermore, this transaction allows Rockwell to drive its overall business to profitability, to improve the Company&#8217;s financial position, to maximize revenue, and to unlock the value of its manufacturing and distribution capabilities.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rockwell is the second largest supplier of life-sustaining hemodialysis concentrates products to dialysis clinics in the United States.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Collectively, this strategic focus affords Rockwell the opportunity to expand its leadership position within a large market opportunity, which currently is valued at $380 million and is anticipated to grow to approximately $500 million by 2026 in the United States alone.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;In light of a very challenging </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">macroeconomic environment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, we are pleased with our performance for the third quarter of 2022.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  We</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> generated our largest quarterly revenue to date, significantly reduced our cash burn rate, and reduced our outstanding debt,&#8221; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">said </font><font style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Mark </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Strobeck, Ph.D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, Rockwell Medical's President and CEO.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8220;The decisions we have made, and continue to make, are consistent with our strategy going forward, which is focused on growing </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rockwell&#8217;s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> revenue-generating businesses and achieving profitability in 2024 to put the Company in a stronger and more stable financial position</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If successful, we expect that our cash balance will be sufficient to fund operations going forward, thereby reducing our reliance on raising money in the capital markets to fund our operations.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FINANCIAL HIGHLIGHTS</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Revenue for the three months ended September 30, 2022 was $18.7 million, which represents a slight increase over second quarter 2022 revenue and the highest quarterly revenue to-date for Rockwell, and a 16.9% increase year-over-year compared to $16.0 million for the three months ended September 30, 2021. Revenue for the nine months ended September 30, 2022 was $53.5 million, which represents a 14.8% increase year-over-year compared to $46.6 million for the nine months ended September 30, 2021. The Company projects total annual revenue for 2022 to be between $65 million and $70 million, which would represent up to a 13% increase over $61.9 million for 2021.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Cash used in operating activities for the three months ended September 30, 2022 was $1.1 million, compared to $5.8 million for the three months ended June 30, 2022, representing an 81% decrease quarter-over-quarter. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Cash and cash equivalents at September 30, 2022 was $27.6 million compared to cash and cash equivalents of $30.8 million at June 30, 2022 and $22.4 million at December 31, 2021. The variance in cash used in operating activities and cash and cash equivalents for the three months ended September 30, 2022 is attributable to paying down debt over the quarter. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Subsequent to the third quarter of 2022, Rockwell reduced its long-term debt to $10 million following a pre-payment of $5 million. This enables the Company to reduce its interest expense over the next year by agreeing to a ten-month interest-only period starting with its first payment on December 1, 2022 and ending on its last payment on September 1, 2023. Taking into account this debt prepayment, the Company&#8217;s cash and cash equivalents as of September 30, 2022 would have been $22.6 million. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This is compared to March 31, 2022 when Rockwell&#8217;s outstanding debt was $19.5 million and cash balance was $9.9 million. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OPERATING HIGHLIGHTS</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Over the third quarter of 2022, Rockwell&#8217;s ability to meet demands for its hemodialysis concentrates products remained consistent despite the Company&#8217;s suppliers experiencing raw materials, equipment, and fuel challenges. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Demand for Rockwell&#8217;s products remains high as other companies continue to face challenges supplying customers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">In the third quarter of 2022, Rockwell&#8217;s partner, Jeil Pharmaceutical, commercially launched TRIFERIC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">in South Korea. Rockwell recognized revenue associated with its license and supply agreements with Jeil totaling $5,200 and $0.3 million for the three and nine months ended September 30, 2022, respectively.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rockwell remains focused on supporting its six international partnerships in China, India, Korea, Turkey, Peru, and Chile with organizations that have exclusive license agreements to develop and commercialize TRIFERIC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> in their respective regions.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">To align with the Company&#8217;s updated strategic direction, Rockwell discontinued its New Drug Applications (&#8220;NDAs&#8221;) for TRIFERIC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and TRIFERIC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> AVNU in the United States. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sustaining TRIFERIC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> commercially in the United States resulted in a loss to Rockwell of approximately $2 million to $3 million, annually. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The decision to discontinue the NDAs was not made lightly as the Company realizes the direct impact this action has on patients currently using these products. TRIFERIC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:700;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and its approved presentations were not discontinued for safety reasons.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">During the third quarter of 2022, Rockwell conducted a microbiological and short-term stability study of Ferric Pyrophosphate Citrate (&#8220;FPC&#8221;) for Home Infusion, in accordance with FDA guidance, to support the Company&#8217;s Investigational New Drug (&#8220;IND&#8221;) application. Preliminary results from the microbiology and short-term stability study indicated that the program would likely not meet the FDA&#8217;s requirements to support the IND application and would require significant capital expenditure and resources to conduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">additional re-formulation work and a Phase 2 study.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result, the Company has put development work associated with FPC for Home Infusion on hold. </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">Rockwell will conduct a pre-IND meeting with the FDA in the fourth quarter of 2022 to discuss the development plan for FPC in Acute Heart Failure and once completed, Rockwell will determine the path forward for this program as the Company works towards profitability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:13.8pt">During and s</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ubsequent to the third quarter of 2022, Rockwell undertook workforce reductions as part of its business restructuring. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rockwell Medical&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 will provide a full analysis of the Company&#8217;s business strategy as well as its third quarter 2022 results.</font></div><div><font><br></font></div><div><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONFERENCE CALL AND WEBCAST DETAILS</font></div><div><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Please call 10 minutes prior to the call to register.</font></div><div><font><br></font></div><div style="margin-top:6pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Date&#58;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Monday, November 14, 2022</font></div><div style="margin-top:6pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Time&#58;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> 8&#58;00am ET</font></div><div style="margin-top:6pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Webcast&#58; </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">www.RockwellMed.com&#47;Results</font></div><div style="margin-top:6pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Live Number&#58;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (888) 660-6347 &#47;&#47; (International) 1 (929) 201-6594</font></div><div style="margin-top:6pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Replay Number&#58;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (800) 770-2030 &#47;&#47; (International) 1 (647) 362-9199</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">  A replay will be available via the replay number and webcast through December 14, 2022. </font></div><div style="margin-top:6pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Access Code&#58;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> 4944610</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div></div><div style="margin-top:6pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Speakers&#58;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Mark Strobeck, Ph.D., President and Chief Executive Officer&#59; and Paul McGarry, SVP, Finance and Chief Accounting Officer</font></div><div style="margin-top:6pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Format&#58;</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Discussion of Rockwell Medical's overall business strategy and third quarter of 2022 operational and financial results followed by Q&#38;A.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Rockwell Medical</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Rockwell Medical is a commercial healthcare company focused on providing life-sustaining products for patients suffering from blood disorders and diseases associated with the kidney. Rockwell is an innovative leader in producing and delivering a portfolio of hemodialysis products, including concentrates (solutions and powders) and related ancillaries, to dialysis providers in the United States and internationally. Rockwell is the second largest supplier of acid and bicarbonate concentrates for dialysis patients in the United States. The Company is dedicated to providing the hemodialysis community with the highest quality products supported by the most reliable delivery service in the industry. For more information, visit </font><font style="color:#0432ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.RockwellMed.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Forward-Looking Statements</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Certain statements in this press release may constitute &#34;forward-looking statements&#34; within the meaning of the federal securities laws. Words such as, &#34;may,&#34; &#34;might,&#34; &#34;will,&#34; &#34;should,&#34; &#34;believe,&#34; &#34;expect,&#34; &#34;anticipate,&#34; &#34;estimate,&#34; &#34;continue,&#34; &#34;could,&#34; &#34;can,&#34; &#34;would,&#34; &#34;develop,&#34; &#34;plan,&#34; &#34;potential,&#34; &#34;predict,&#34; &#34;forecast,&#34; &#34;project,&#34; &#34;intend,&#34; &#34;look forward to,&#34; &#34;remain confident&#34; or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. There can be no assurance that&#58; Rockwell Medical will achieve its projected total annual revenue for 2022 and beyond</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#59;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Rockwell Medical</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> will be able to achieve planned cost savings to operate its concentrates business profitability or achieve the other components of its strategy&#59; Rockwell Medical will achieve profitability&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">termination of the exclusive distribution agreement with Baxter will help improve Rockwell&#8217;s balance sheet or long-term viability&#59; or Rockwell Medical&#8217;s future cash balance will be sufficient to fund operations going forward</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the &#34;Risk Factors&#34; section of our Annual Report on Form 10-K for the year ended December 31, 2021, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.</font></div><div style="margin-top:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"># # #</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INVESTOR RELATION CONTACT&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Heather R. Hunter</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">SVP, Chief Corporate Affairs Officer</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(248) 432-1362</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">IR&#64;RockwellMed.com</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Financial Tables Follow</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:112%">###</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.294%"><tr><td style="width:1.0%"></td><td style="width:57.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</font></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(Dollars In Thousands)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">September 30,</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;</font></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31,</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2022</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2021</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">(Unaudited)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash and Cash Equivalents</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">27,564&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">22,438&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total Assets</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">54,186&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">48,574&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total Liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">38,050&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">46,039&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total Stockholders&#8217; Equity </font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">16,136&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,535&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common Stock Outstanding</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,152,673&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,544,225&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock and common stock equivalents*</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">20,056,596&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,511,666&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">*Common stock and common stock equivalents&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,152,673&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,544,225&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Preferred stock converted</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,363,636&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock warrants (pre-funded)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,311,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock and pre-funded stock warrants</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">19,827,309&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,544,225&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Options to purchase common stock</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,311,691&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">528,591&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Restricted stock awards</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">891&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,118&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Restricted stock units</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">125,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">29,289&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock warrants</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,944,378&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,402,442&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total common stock and common stock equivalents</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">31,209,269&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,511,666&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><img alt="image_2a.jpg" src="image_2a.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:239px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ROCKWELL MEDICAL, INC. AND SUBSIDIARIES</font></td></tr><tr><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS</font></td></tr><tr><td colspan="39" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">(In Thousands, Except Shares and Per Share Amounts)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;</font></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Three Months Ended September 30,&#160;2022</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;</font></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Three Months Ended September 30,&#160;2021</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;</font></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Nine Months Ended September 30, 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">&#160;&#160;&#160;&#160;</font></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%">Nine Months Ended September 30, 2021</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Net Sales</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">18,691&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">15,988&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">53,497&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">46,599&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cost of Sales</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">17,914&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">16,317&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">51,760&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">46,788&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gross Profit (Loss)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">777&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(329)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,737&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(189)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and Product Development</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">469&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,221&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,963&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,445&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Selling and Marketing</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">762&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,541&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,743&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,860&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and Administrative</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,254&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,881&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,845&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,483&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Operating Loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,708)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(6,972)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(14,814)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(21,977)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Other (Expense) Income </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Realized Gain on Investments</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest Expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(476)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(609)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,497)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#160;</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,772)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest Income</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(10)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">17&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Total Other Expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(482)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(609)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,503)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,756)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Net Loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(4,190)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(7,581)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(16,317)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(23,733)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Basic and Diluted Net Loss per Share</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.40)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.89)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1.75)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2.79)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Basic and Diluted Weighted Average Shares Outstanding</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,528,148&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,534,740&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,229,788&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,520,603&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rmti-20221114.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e88dabdf-1e2f-48bb-b177-efab24ab0ca7,g:91dfe646-35bd-407a-a5c7-cb47f94d99a2-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rmti="http://rockwellmed.com/20221114" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://rockwellmed.com/20221114">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20221114_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmti-20221114_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://rockwellmed.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rmti-20221114_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e88dabdf-1e2f-48bb-b177-efab24ab0ca7,g:91dfe646-35bd-407a-a5c7-cb47f94d99a2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_4b15ea96-cad0-4285-bd4b-e593b47d5a06_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_19487da2-5cce-49f4-96df-1b57080d846e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_40e21702-1f6c-43a6-8d8d-7cc22031f84f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_95549a19-a354-4df3-9438-45d0cf2af47c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d986faaa-c9bf-42bf-a81c-9678668b9c94_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_24abab82-23c4-43ac-9f3c-9beb9d257976_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_c6edafce-9f02-458c-9d25-ceae009b57df_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_70ae803d-3561-49e6-af1d-6ca7e3daa117_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d9e1c874-19c9-45b8-8b19-0bb78e92d714_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7402acb2-b211-483b-a635-e2f0d4881116_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0fb5320f-aa8b-4223-a68e-82ae85b3f85a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_1de7ed7f-271e-447c-8263-f04937d82283_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6d881b0a-0211-4a6a-af66-c71e2ccb6ca2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_61b56c2f-01ab-4908-81a4-456b6c85fbbd_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b57d42ac-1a53-42fd-8afc-2d80aed80970_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cf996be2-3ca1-4616-8975-09adf9cb6524_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f23f749b-cbb2-4698-b857-c5ffcab47d38_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6bc9c836-0046-4c00-ac79-2d61f0433c43_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_758aeaab-3e7d-4407-abba-d1bf1c6ae30e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_a21a08dc-5532-4a5b-a088-82237e4b2fbd_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c416441c-da09-4c44-b3eb-6d377af09f9b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3d9d9d7c-a382-49c8-9ecd-d6acfd03e373_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_57b64724-5a6c-43f3-babf-f735d067a0cc_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rmti-20221114_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:e88dabdf-1e2f-48bb-b177-efab24ab0ca7,g:91dfe646-35bd-407a-a5c7-cb47f94d99a2-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://rockwellmed.com/role/Cover" xlink:type="simple" xlink:href="rmti-20221114.xsd#Cover"/>
  <link:presentationLink xlink:role="http://rockwellmed.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_99452b10-c53f-44b0-b176-e7be5191406b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_DocumentType_99452b10-c53f-44b0-b176-e7be5191406b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8b13d0ae-a6ed-44b7-9aae-bf76d50b59da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_DocumentPeriodEndDate_8b13d0ae-a6ed-44b7-9aae-bf76d50b59da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f487e731-fc9c-4417-b843-15274642232f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_EntityRegistrantName_f487e731-fc9c-4417-b843-15274642232f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_428389d8-1b5c-4dfb-a977-791bf553e03a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_428389d8-1b5c-4dfb-a977-791bf553e03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d0fef125-8a79-45fc-a592-faa24a555f49" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_EntityFileNumber_d0fef125-8a79-45fc-a592-faa24a555f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ae3edf2e-1a29-4c75-9b96-868eab03d213" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_EntityTaxIdentificationNumber_ae3edf2e-1a29-4c75-9b96-868eab03d213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fe348377-3a95-460b-b8ef-8f6fff381dfb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_EntityAddressAddressLine1_fe348377-3a95-460b-b8ef-8f6fff381dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1719400d-a773-4abf-860c-b1105b372380" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_EntityAddressCityOrTown_1719400d-a773-4abf-860c-b1105b372380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_bc705c1e-37f6-452f-8f77-1b79fad92084" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_EntityAddressStateOrProvince_bc705c1e-37f6-452f-8f77-1b79fad92084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_94de85f5-c998-414f-833b-d60347e1c5cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_EntityAddressPostalZipCode_94de85f5-c998-414f-833b-d60347e1c5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f32b5d02-751a-4761-afea-49120cde4fe2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_CityAreaCode_f32b5d02-751a-4761-afea-49120cde4fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_510bc885-9269-4248-85d1-4e850688dbc9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_LocalPhoneNumber_510bc885-9269-4248-85d1-4e850688dbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_ec643d21-b2ce-4180-8f31-df44a1cab9a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_WrittenCommunications_ec643d21-b2ce-4180-8f31-df44a1cab9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_1e19fbd1-8410-4091-b546-b788bda0c16e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_SolicitingMaterial_1e19fbd1-8410-4091-b546-b788bda0c16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_c0fadaf2-e18a-4049-a109-524c54a0386e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_PreCommencementTenderOffer_c0fadaf2-e18a-4049-a109-524c54a0386e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_2cdf24eb-df96-4d49-b81e-005e8d13fef5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_2cdf24eb-df96-4d49-b81e-005e8d13fef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_60cae04b-caca-46fc-ae99-146758ef0911" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_Security12bTitle_60cae04b-caca-46fc-ae99-146758ef0911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_363faa69-0e95-4f60-a7f8-2099b8cc0420" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_TradingSymbol_363faa69-0e95-4f60-a7f8-2099b8cc0420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_afca8a73-1e2d-4535-845e-d591286935d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_SecurityExchangeName_afca8a73-1e2d-4535-845e-d591286935d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_21b6f778-bc72-4f52-8aae-a3964044134a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_EntityEmergingGrowthCompany_21b6f778-bc72-4f52-8aae-a3964044134a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_cd1c5a28-9629-4516-bd10-8eae170bc3c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_EntityCentralIndexKey_cd1c5a28-9629-4516-bd10-8eae170bc3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0d928d65-ab9e-47bd-b8b7-a83ba142ed4b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2f88ff98-7ba2-4a2b-bb28-d53ae6a11e3a" xlink:to="loc_dei_AmendmentFlag_0d928d65-ab9e-47bd-b8b7-a83ba142ed4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_2a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_2a.jpg
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MP6BCY#]*B:(C,6YDZQ&.WUF6O!G!.P\X03E!A!5LA-2Q6^F\#%;N'QU*]+J
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M:/CB\,N3E+@@&2*LWQCAW'1YV3Q(=6F9V>DM.ZI>?V7/COH*C=KQ6R E!9D
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M,=4]@B=FM::8(#HQ^$5B?:+($;[?$&7ZE>MT]H[@'5E<7%H'0Z=_1'F [N2
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M3QQNL4*B)J'R1VN1C6&(^S_^[!/B"&:F*4*ZK%7(5$>4EZF!1A+7<O.R*(A
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M[\<-6UM9*JJMSLYY <.)1I\F[UTT0?<0,I-&3L>XH45.$Z\?C9S>4$M+N&^
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M>&CX>A8"I$L4%P*><U(;7N[P,!I-\'D\YOGON66ND\@%G,P;R %8W:F9.TO
MR^HJ,6O%V6D4(X"LD^/@S.>$Y<"9YC#!+8XM+H_B!)I8'*$#_;)$(AG+<0^Q
M?U3>#/3<<.5CANVM0B JICLZO;9*[35J@U;FDP.>AOI"71Q*94.^O-U99 :,
M3!3U*2+Y7WRD%+%>GI8.;X[D^QVR[7T2TQK\7I1YN]@B#XJ0WKG-;Q-Q@3UF
MBPOU +>EU7M<1$[[MW_A).7("%/6S6[>H]2,]/3<O$QBQM6KS _F8W!N%>-
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MHC5LI'>GV? %4-F9$$TJC+&E:?=I!#R0?U0L,30)%S6Z)X$WS !AG-_I1T
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M*4EJ/2^/UB:?M $$! &):4+,QYF!;X9$4<@FEC127J[?Z80VH>Y,3,]V]8W
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A\DE)""0AD(1 $@+_?V=^N>D[9%*(     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140673426245408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 14,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ROCKWELL MEDICAL,&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-3317208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">30142 S. Wixom Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wixom<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">48393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">960-9009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RMTI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001041024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>rmti-20221114_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rmti-20221114.xsd" xlink:type="simple"/>
    <context id="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2022-11-14</startDate>
            <endDate>2022-11-14</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF80L2ZyYWc6NDAyMzAwZTgwYWUzNGMwZjllYzViZGQ0MDMyZTY5ZDEvdGFibGU6NDg3MzM2ZTY2YjI0NGJlZGI3MWNhODBhZDNjYmVjYjAvdGFibGVyYW5nZTo0ODczMzZlNjZiMjQ0YmVkYjcxY2E4MGFkM2NiZWNiMF8xLTEtMS0xLTQ4NDU4_122f734c-4cfc-4ab2-87ba-8458134a1acd">0001041024</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF80L2ZyYWc6NDAyMzAwZTgwYWUzNGMwZjllYzViZGQ0MDMyZTY5ZDEvdGFibGU6NDg3MzM2ZTY2YjI0NGJlZGI3MWNhODBhZDNjYmVjYjAvdGFibGVyYW5nZTo0ODczMzZlNjZiMjQ0YmVkYjcxY2E4MGFkM2NiZWNiMF8yLTEtMS0xLTQ4NDU4_25614b7e-4da3-4486-b88a-6564a11a62dd">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNTAz_0b4c65e5-3aaa-4946-8de5-7ca763f005d6">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yMzU_4082c4e9-3c10-49a3-a068-3032b2c37164">2022-11-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNTAw_808195a7-eafe-45a1-8149-e0ce361fc4b4">ROCKWELL MEDICAL,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6M2ZlMDQwMTEzZDM3NGYxYzgwMGU1ZTI5ZTNlZWViZTMvdGFibGVyYW5nZTozZmUwNDAxMTNkMzc0ZjFjODAwZTVlMjllM2VlZWJlM18wLTAtMS0xLTQ4NDU4_a8b6430d-1a06-40b3-b697-6725f63b4b9e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6M2ZlMDQwMTEzZDM3NGYxYzgwMGU1ZTI5ZTNlZWViZTMvdGFibGVyYW5nZTozZmUwNDAxMTNkMzc0ZjFjODAwZTVlMjllM2VlZWJlM18wLTEtMS0xLTQ4NDU4_b8b8304b-26bf-458d-886a-9bb340e26d9f">000-23661</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6M2ZlMDQwMTEzZDM3NGYxYzgwMGU1ZTI5ZTNlZWViZTMvdGFibGVyYW5nZTozZmUwNDAxMTNkMzc0ZjFjODAwZTVlMjllM2VlZWJlM18wLTItMS0xLTQ4NDU4_1c765c1f-be6a-4181-b1cc-d1b360cda391">38-3317208</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNTA1_5b76aa98-1808-4ca6-a433-5ff0cbda9aff">30142 S. Wixom Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNTAx_a4207dee-b267-4971-8f98-ebea5fa8db29">Wixom</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNTA2_82f06f42-ceda-42ce-937c-8dbab0522677">MI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNDk2_f0dd9779-bbf6-4943-b376-cfe5abeac9d6">48393</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNDk3_94d47264-98db-45c7-a657-c1098d8681dd">248</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNDk4_53671f39-3a31-4808-b722-1a1f393d8a1b">960-9009</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6Y2Q4ZTFiYjNjNjFhNGY3MzliNDczYjE1MmMzMWRhZGQvdGFibGVyYW5nZTpjZDhlMWJiM2M2MWE0ZjczOWI0NzNiMTUyYzMxZGFkZF8wLTEtMS0xLTQ4NDU4_f7709ec4-5afc-427b-82c6-ab8340e70c36">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6ODk3MjVlMjViNTYwNGExMDk1NTI2ZDFiNWY4ZjQyNWIvdGFibGVyYW5nZTo4OTcyNWUyNWI1NjA0YTEwOTU1MjZkMWI1ZjhmNDI1Yl8wLTEtMS0xLTQ4NDU4_5ffa2d67-e119-4c64-800f-9d4f5c1fcc57">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6YzhiZWM2ODM1YTkzNGE3ZTgyMTM3Njk1YTc0MjJmMTYvdGFibGVyYW5nZTpjOGJlYzY4MzVhOTM0YTdlODIxMzc2OTVhNzQyMmYxNl8wLTEtMS0xLTQ4NDU4_16a1b10c-51cd-46b8-8b8f-6edd8b61c9a0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6MmMyMDA1Mjc0Nzk2NDQwMThmN2EyYWU0MDQwYmQ4NTcvdGFibGVyYW5nZToyYzIwMDUyNzQ3OTY0NDAxOGY3YTJhZTQwNDBiZDg1N18wLTEtMS0xLTQ4NDU4_2fa11c2c-cdc3-4db2-9d91-0a9aff7cb0e1">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6MWU0YTc4ZWE4OGZmNGQ4MTliYjI4Y2MxM2NjZWQ4NDAvdGFibGVyYW5nZToxZTRhNzhlYTg4ZmY0ZDgxOWJiMjhjYzEzY2NlZDg0MF8xLTAtMS0xLTQ4NDU4_c543c355-eeb9-4e9a-8172-cd901ae91f99">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6MWU0YTc4ZWE4OGZmNGQ4MTliYjI4Y2MxM2NjZWQ4NDAvdGFibGVyYW5nZToxZTRhNzhlYTg4ZmY0ZDgxOWJiMjhjYzEzY2NlZDg0MF8xLTItMS0xLTQ4NDU4_c0b4019b-5feb-405f-b3dd-cdd1e2e1399f">RMTI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGFibGU6MWU0YTc4ZWE4OGZmNGQ4MTliYjI4Y2MxM2NjZWQ4NDAvdGFibGVyYW5nZToxZTRhNzhlYTg4ZmY0ZDgxOWJiMjhjYzEzY2NlZDg0MF8xLTQtMS0xLTQ4NDU4L3RleHRyZWdpb246YzU5NmQwYTdhNThjNGE0NWIzYzYxNzU5NzE2OWEyOTFfNA_4127c66e-198b-44cd-936c-dbe186ac4177">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114"
      id="id3VybDovL2RvY3MudjEvZG9jOjNhMTdhNmIzMmJlNjRjMzRhMDhhYTU3OGY3NmFkYzQ0L3NlYzozYTE3YTZiMzJiZTY0YzM0YTA4YWE1NzhmNzZhZGM0NF8xL2ZyYWc6MGE0M2Q5NGEyMDFhNDllZmE0YzgzNzNlMTA2NmIxYTYvdGV4dHJlZ2lvbjowYTQzZDk0YTIwMWE0OWVmYTRjODM3M2UxMDY2YjFhNl8yNTAy_6868fbe9-a34a-4d04-8dfd-d17cec2c83a3">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<F]P<R]A<' N>&UL4$L! A0#%     @ 33%N58ZQ4K3N    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 33%N
M59E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !-,6Y5PG_G,4$$  !W$   &
M@($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 33%N
M59^@&_"Q @  X@P   T              ( !A P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " !-,6Y5EXJ[',     3 @  "P              @ %@#P
M7W)E;',O+G)E;'-02P$"% ,4    " !-,6Y5JL0B%C,!   B @  #P
M        @ %)$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 33%N520>
MFZ*M    ^ $  !H              ( !J1$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ 33%N5660>9(9 0  SP,  !,
M     ( !CA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&V!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="rmti-20221114.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="rmti-20221114.htm">rmti-20221114.htm</File>
    <File>rmti-20221114.xsd</File>
    <File>rmti-20221114_lab.xml</File>
    <File>rmti-20221114_pre.xml</File>
    <File>rmtiq32022earningspr-final.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rmti-20221114.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "rmti-20221114.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rmti-20221114_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rmti-20221114_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rmti-20221114.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "rmti",
   "nsuri": "http://rockwellmed.com/20221114",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20221114.htm",
      "contextRef": "i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://rockwellmed.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmti-20221114.htm",
      "contextRef": "i17b2998fb4fb44ba8bda3dfbb28cc201_D20221114-20221114",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-22-029592-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-029592-xbrl.zip
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M20;340$D1"1*"$NEZTY0RNA"1_"Y?!Y?/M@/KB)11S*>]^.RX*J/')!Y)U#
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M*8T2#WL<HUC8";ICI)$*6Z$%;;A@B==6X%T$FPK]&6@;1O#VC#D(_P ;/1)
ME^>!$\&! '<3PJ$37!/#.\[51;)8_:>J"^%/D2<"/_%452)C!E%(8H@YYC!A
M+ B\T)<82;NDH!EEI EA!?'E^@#48,'G7-@F!!VQILF@)UW#) )[IAP2P1XF
M>B0!G=>!$\">P';%O\_87OB7):F;71</<UK,IFD4H93X*21AA"#B,H0I"C%$
M$?>8#(A$"3,5>\OSV 2^ @>6Z,SEW*;KL(2=23BR; WCMQ*I-E8G8;8]#29&
M;0"; M0;N,ZV'[*96!6&/,6Q)(1 EE*I;J75"\$^4^5W@N,8TY2ER&Z2?7(^
M-NFM9HP:H&-YO4&<Z23J1L<P<Z<)$PZSY6[(/2;)#6<#SXV[8>Q.B1H;>U%^
M*<59,9\+A:M>X?FX6-R*\K)NCY6?I5376KT>0R@.8! R5%?"2I\R5"]4T)0'
M49(FQOVN0X.-3;0*+V0;@,$2,5A"!@UF<QD?I/JPK)^3P"/+O!=W5L(W)<4I
M$1QT/EAB, US,U$8GV.?."Z*6<:R2A4&?Q"EQ8S,IBP6G$@F5()0=\XHPBI+
MJ P!F2#"\U(:)=SXIGG7_=B2PQ-"L(9HG@LT[!U6?S].CJQW&SJLY-T=M9.@
M->X&DW!W*)NBW6/5L\5UI@X_EY?%73Y-/"*P%W(81K$/42IB2*3/8<Q((D).
MB.\G3@VNIS'&)MCMIDV-5/$(:JR.K:T-0BT;6VXT#=S6,F+(O:6URT'_AM:&
MSU_3SMH-JK.9I3%U%?C'G!7E35$V??&+2N6-L^(VK\J'LX(+=:,M?(83!'UU
M2ZTF9HHAIGX*/4H3+-* )[[EC?;>\48J_!;FEZ!!75_=*^2@AFZ;!_;S;IH3
MGHW-8?)#+R(=TH41/3U2QW[_ Z<1HV!W4XK9:?;II7YD<?;ENLC7O:<$>0%A
M-( T\%7A@$,*21Q&4 32XPACW_>-^P';SL>6.!I\H %HW;3;(>YP,NA#QY&5
M;\&$E<"[0G92\XZSP:3;%<:F3CMM>A;U7XI%16;_SFZ:*<>3- H#3T)",(4H
M"$(E3RP@#E2]']%0XH@XU?6M8<8FU.W"=0D6*+1.L[J66<L"WYFO@6M\4ZK<
MRWPM$_TK_;;;7U/L:T/KK/?UUO;R_UYF527RNK-WFZ^>A5E,?2X2P1,)@\07
M$*&$*=''(90>2L.$XR# H:GRM2.,3?0KD*"-TESK>AH/R[PW.4=6N"4O5L+>
M&[N3IO4>!Y/SWH VE;S?T%[$]<W_NU*09FZ)N2J<J4>@UQ35)":0R#B&3$DY
M8(S&C 2FVMUT/#;)-@VE&ISEM-PBZ[!"72DXLC -H[<2I"Y4)QVV' TF/QW\
M3=5I/W<06_%3E._HHBH)JZ:Q3Z.8!1)Z/E$U<NIAB'V"((IBI30<24JYL=HV
M/8].;C4X\)\UO/]:"*Y%F('B7&DXMN1,&; 3G2Y:-]6U/ TG.UT +=UI#1Q6
MB06[51/G@Q_0RZR:B6F]"(P"PJ!/HE#=GTH.,9$,!AQ[1*B7-/&,UXBWG(]-
M?@TH4$C@!W^C?P=KN!:KQ-OL'19B'TZ.K$5;.NQ6B3OB=ELCWG8VW IQ1QBM
M]>$N&WMYKG_8?ZE.G3*9IC$5 0P9445H[,<0ITD$O91PF:HB- J,5XDV'8]-
MEH^[&=3@S,78XNJP$%T9.+((S8*WDIXN4B?9M1P-)CD=_$VY:3^WE]H[Y8/7
M?C[,R-54!J%,4$HAHS106DLQI#A*((ND9*3^'7&(3;76\CPVL3V" S4Z<[6U
MZ3HL-V<2CJPWP_BM!*>-U4EQ;4^#24X;P*;F] ;NY>?[>W:MOA7Q27U3TYBR
ME.$PAIZ'8HB8YT'"DE25H+$O/12&#!DW2G4#C$V":XQ@#1+4*.VKT!:)YI6H
M*S5'%J8E*T[%J"[T7@5IR^'@1:DN'%UAJK5S7>7\*JZR^C8TKYKK+HDP$810
M&(J$0X2\!!)*">0^E3Z+B0@]RU_KMP<8FWA7RW5/("W%JR7QL'C[4G-D\5JR
MXK!VJ0^]QZKEEL.!UROUX>RN5';8N8KW_5R45UE^]<^RN*NNSXKY#<D?IB3P
MB8<Y@U$4JN*71!2JOS'$01 F M% FO=?]XPS4BFOL8(E6+!":RMI/;6FRNY-
MV# "M^7*0>A[F>BA=[W?@66_-[A=]>\W[_F<4O-0XN?R2UG\S!3\*4-^C)#/
M("=>JLIPA" -!84Q#Y.$2"^5*75Z4FEKH)&F@<<'<!X?GUT#=GQ::9M?TU30
MG[5A<H$#8>[/+'6PT?^II6W'O^:YI8[P.I]<ZK)W[S@_[I_XN_(\#7FJ_B4,
MDA"KBD#=GL-4, YY3)CD7BC"Q/B67#O"V)+ 8QMVB1(HF*#&:=^.;A-IWI=V
MIF>H!K4I,TZ]:FWTO9K6;8^#=Z^U >G:V'K#WAL';/Z./4IHC)( P8@TFV?)
M$%)")91)&'$O3HC'C/?3Z1YF;)+>^<'[L^P2T&M_@/^3G0&.OB7 D38#&,,V
M '8; -C\]'_SFSA71Z<OUN]DR[W'3U_\#U!+ P04    " !-,6Y5Z9O_<ZH&
M  #:,   %0   ')M=&DM,C R,C$Q,31?<')E+GAM;-6:6T_D.!;'W_D4M;6O
M:\K7V$8-(Y;I7J%EIE$WHQ[M2\F78X@ZE2!7:.#;[TF ;JZ:#"F)]$M=$B?'
M_I]?['..\^Z7JU4U^P9Y73;U[IQMT_D,ZM#$LC[=G?]Q\H&8^2][6UOO_D'(
MG__^=#3[M0D7*ZC;V4$&UT*<79;MV>Q+A/776<K-:O:ER5_+;XZ0O?ZB@^;\
M.I>G9^V,4\X?G\T[8$QT/B;"@"<BC??$,ZT)).>Y=)X&I_]UNF-93%#(@@CE
M(Y%4.^)4T"1XJ9.5T5K'^YM69?UUI_OP;@TS'%R][O_NSL_:]GQGL;B\O-R^
M\KG:;O+I@E,J%G>MY[?-KYZTOQ1]:V:M7?1GOS==E\\UQ-NRQ9^_'7T.9[!R
MI*S7K:M#9V!=[JS[@T=-<&VO^5_V:_9BB^X?N6M&ND.$<2+8]M4ZSO>V9K,;
M.7)3P2=(L^[[CT^'WTWF)GR]A*I:0=P.S6K1G5\<-$@#]K2_LKT^A]WYNER=
M5W!W["Q#VIWG55N2SJ6,,=G9^^?-A8L?9L\SK)&4?IA'>.#V^L[*W^X"7+50
M1[@9U9V!J@D/&E6=ILWW*ROGH>J/+B.4R_ZN^W[=9A?:)4_&I&0-T1[)D8XC
M=YX;$I5P4#C&0+B'(^YZO,8N]RY80]@^;;XM\,:+3H7N1R]'+\43<S>RO*[?
M=T_<";9=6BL5]XR2H 0^+M+3[G$I"&@/BEDF:>%'=?N^M8>]ON_._1QF38Z0
M<<JX,^=R>.#:I[C>MEB<NXPW(N&LK.+=U=W<L0E?M<T&E+MQ"W9W/L-1)\@9
MXM&-5UX<7#^R%B=2Z%MNPN/'D,LFOJ_CKSC3+HUG(E('Q!40NP%H8AW^]4D7
M45&O;!Q'[+-F!S' I\_ Z[5\8QC>UVW97G^"T[)3HFY_=RM8)FDT:,%("C9@
M_YDFWDB<_177LI"<"YY&L?"<U4$HB.FB,%K)29!PB-%9/F]R+_QGU!\.FHNZ
MS=<'382EY$88&PUA7N%P8O+$60RGM&4^*26 CES6!G1B$"=RZIQL3N=)8/.A
MK.#WBY6'O(PT06)<$>.T)5*E@+&TY20YAQ&W4BI)NP%&?E@<!(2:.A"O5' 2
MWC]Q5X<1M2I3>9-VW [$@8"8.!#F. XD:$6LMP4QA0',O43D3&P A1?,#^*B
MF#H7F]!V$I#LQX@N6-]^8<8&;)E 2"-P8A/.*B(+BM(82,2D(J4D#*;EX_*-
M%TT/@D-/'8ZQFDX)C /\^3&?-)?UDFEF):61.*T%BN*Q]P4-F%$QJKS07!BZ
M.2Q^&!X$A?E)H'BEGE-"HH^+/N;CW'PKZP!+'S15@0$1.A6X,/*.:B2=>6V3
MBY93(S?'Q2/K@^"P/PD<8Y2=$B''S;IUU?_*\SYLMC*"44F18%$?R22.0@A/
M8D&%U,"""F%S?#RP/:R817\2/%XOZQO#T4UZ^QE<W^\DN%>1<J(5<T3J@A&7
M ']9QFF((!/P43C<MS8,@ F7,U\MW1N[O-OJJ([/FOHN?5*,^F ,QL.\P,B8
M2T.,BHQ(A)@6QD0?QB6@CRT.<_V$JYBC)'QC]W_)9=M"?="L5A?U;8JT7D(H
M9)<"$<\#X)1E**YG@I&8I'0L.&^=&<7 LV:'@3#A&N9X,=^8AL]-58:R+>O3
MWS# R:6KE@R831[A-9)1(JG%<2A9$*^-\='1P H8A<)3F\,XF'"-<J2,;PS!
M<8:.8,# MM^?Z[9V\\>$_5@&BM&L2YP ,[B:46F)8]02Q650TE%A1L+PLNUA
M4$RX3KDA6:<%Q^%Z?0'Y_EAXB(E+P/ V64R%(H[%&\R,*%5@(A,)DMHD(D]Z
M, R4"1<N-RKQ6R\H$"YP4;QFW)^4;07+@@8'5'H27$#4BZXX#]82)@NM#"2<
M&-FXY>21Q6$X3+A4.4K"-W;_27;=NVJ?KU>^J9:B$,DYC(@I=*755%#B=#+H
M/VN]"8%*/JXN^<#<,,=/N!SY>O$F\M"_OPIGKCZ%?BO?I>",TZ)[E3 2J83"
M4$@!JH YL2FL4%%OY,&_;W48 Q.N.HZ6<A+5QO<KR*>(\G]R<]F>X>)V[NKK
M)6>^2%H;XH-&39+BQ'2O^3AA"XR!)!-R$V]#/&M\V(M3DZ\WCA=V$GP<H&39
M58<8XES]%ZZ7(;*@'*I@BVYS5C',DR*F308<,$U]$&$3&UB/S YC8L(ER/%B
MOC$-^QCOQB[F_5"YTR6-EIM8*.*\!2*UCQCF>DV<$=XQR2'*<;O;#\P-\_Z$
MJY"O%V]C7G^W>"+>$1[8V[H]T7UT+\/O;?T?4$L#!!0    ( $TQ;E6ACI61
M6R$  &'% 0 >    <FUT:7$S,C R,F5A<FYI;F=S<'(M9FEN86PN:'1M[5UK
M4]M*TO[^_HK9).<LV9*-)=\AFRH'2,(N 0XXF]I/6[(TMK7(DH\N$/;7O]T]
M(UF^@2$8V=8D%8(M:333_4S?IJ?GPU^.+XZZ_[X\8<-HY+++[Y_.3H_8F]+^
M_H_JT?[^<?>8?>U^.V.U<D5GW<#T0B=R?,]T]_=/SM^P-\,H&A_L[]_=W97O
MJF4_&.QWK_:QJ=J^Z_LA+]N1_>;C!_P&?G+3_OA_'_Y2*K%CWXI'W(N8%7 S
MXC:+0\<;L!\V#V]8J23O.O+']X$S&$;,J!@&^^$'-\ZM*:Y'3N3RCTD['_;%
MYP_[])(//=^^__C!=FZ98__]C=-OVJV:V>MQO=ZJZ96FV6HV:S5#;QJ-'K=,
M\S\Z='(?;A?/A-&]R__^9N1XI2'']Q\TC7%T>.?8T?! KU1^>S-]GQD,X-:>
M'T7^Z* UCN"R,QHPTXW@W2-SP/]CF.7_C@=O6!A8<U^)1N2+ZNWQS\/I!NOP
MZEL>1(YENB73=0;>0<1_1O*R[)51A0?AO7T?B"J;M'S7#P[>5NC/(5XI]<V1
MX]X?_/4(VND%SE^U$%A:"GG@],4-H?,_?J#K\$KZ>"=Z58/G7<?C"3ETHPXT
M^/VMWJ@<_OI/]E(-+?OY81\'LS)QNLZ(A^R<W[$K?V1ZRXADS!"IN9!()S^'
M3L^)6+M=UI-^"*3-X8VX*AAL :9YL#H_5^QR];$NZ]CE*]^ZN>.NR[YQ&T''
M+@/_UH&IR3[A-.5AR*ZC *;MX)Y]']OP"S,]FW4\SX\]"V[K#IW 9G_$9@"#
M$'/WL^.9GN5 8WCKQ9C#\R1(V!4/8S<*V31QZ(?XHA=\G+LV,_4B?WS0@+&-
M3=L&.5)R>3\ZJ.(W1%/'LX&>!R5=S,T5:=H)H+NK,G]^AE1HAK0,H[%N_%&+
M!TX$T+$>063EMVD:Z=4RT21EN1.R@(=1$%M1'*!(=H UO83MCL>B(6?AT ^B
M$O!VQ"*?V8%SR^&I6^[% @G\YQ@UA>\Q?SR&6V,/M 9/'Q\$_ATV/>0CWP8:
MWX?P5N#D#8_H\6@8^/%@"+?#*[P$)^.A&8Q,B\<D"%EHNM#B/&H4,EX6&9_N
M@34WR*YH"&P*Q<1W+ "!TX\TEB('F,XM  L@PK2&#L"!C0._#R_O.:X3W2/W
M0134-&R#>P- @D?H\D&YF=! /Q418U^8&1K!(>!V;'%"SI$_ F3=(_'TYB%"
MU77@&<Y\@2S+'.-@)9BH+_T8FNC'@&8^P3$B,!HJ[+R65#'!1K/!RD-VNS[<
M1K+#YCV8\(. <S(%$3BH_-B=$PWIUIB4BYT!G>T$ #* QN]OZ^U#T!T(#5NT
MU _\$7NGUQF,UT7A PV^TRO)1\7M=7-;:H [,P2ZM\K-E!%]/Z#I&9%=\&?&
M+M#8W="QAC"1QZ!V@, AW3B$5X$62FYU[U/U$ODE,CBPR01>BK-KYNR1&0[!
M0\,)C"J=;#=0"";,Q%NAV07/R_I*+#<]UM)_@TF+SE_(20$(NX);OC=]]Y.L
MPI>FX:P;M(AB;S[^<'[Z(XU] QP[ Q.4UCD,:-2# >B@[+*#6&_O%H.,D;+4
M#]FL5:^Q4\\JLSU"8>4PN4P?X7;)/WDUHWCAXGNV=VZ&MODG2.$6M/RM>_H>
MV,HL?S3B :EP<,/=:&B9H'4M\2Q PB(, 3K&Y% @AERGSTMA'$:FX^%GN (B
M'<0  F@,.".9$,;]/B=SE(1\S_5]$/I.Z <V#T*R$N 3@@D^A*$/74"]08H$
M1W'CV!Z_UT!ZV.:]?#M<!R *%8-]RIHBJ:$0)GX.OL*4#H[08_TIC\;/>#2!
M]&@6SP&A":_Y.!(@J58$2,I/\X!>WYM%-'WZ?GUZ?G)]S:Z[5YWNR9=_L^^7
MQ_#+1DW3Q1/A6/@S\PSQ^U(NS?F]_-9T8T)2U@OBH?12P,#U(\ G8@!Y+=PB
MNC@Q<K )7F9??$*O']R9@9UYU9V#EB_.#'H'[\,M"$0O]9)>)WBQF&8+;.Y<
M99FT DH#[B5*:,*5Q):PX@#\B\A%C\-R8YL39:><35 S&&'!N9WQ;I%Q,SXG
M( 3>!*[.6$SG[M7IYY.KTZ.U4*%1KC57H,-AXAX=@/L#/;WEAVCAE*KE6FL^
M5-@#H8@M4+BN65N3M;$:_S0@J CT]N, L!4 N6_!SB/S'TP+Z;Z5D E>B%&%
M&:??!OZ[_ICN!RD^",Q1*)Q$X7)*#9)Q.L$'&,=1UGG$%YDHV&&*0@_PX9$/
M:@I44,_E"[S0113KF=8-3%#P+4N2>'WZ<_A:,[.<IUA@"X52[C3IP!26RA>%
M.O <C$LI43,B-\\9L&J0I,PNO.F81W)_./, XE?:3R#7T%#ON_Z=L)-0[CTB
M,IU(J""*QH!8#,$PRDY+"MJ1.Q8(5::1;N.!T&ZIN89Q0#$Y@0>]P#>Q&6%V
M,;("TSLQ(-CWP4G(V>!9C6'7<2_D?\8R/K&*\3"Q$J.A&2&!*:9J6G_&3AI1
M!6LU"IQ>C/*%T1(7D?!A136QC9&YG\R?D91?0_"^*(YB4R>!,2#$(@$?_A-T
M(,G2J7=.PBXBQ')A13Y:HP8:HWIM \7+:W%\VC03;.-"10!#/0:&\0,\ D,N
M\D?HE CC@^+<?DAZ#:;;2%J68GT'OIBTDGQ##"7OB87W(3@)\COJ3H\/8#Z"
M1G>Q81$-<TG+>3#ZR<ME"-V7JN^[YR"3KR/JXYR=X]X7F-\_T$G,>K\4699&
M9(:D2#68@?\%B@,I1019FY+0/3"T2$(G$U^RC)%AD1'Y[_1*&I9$^3I9._%B
MY$:R4.+QGQ'KPS#ON1F$Y5Q=@5QY]%F8BS@)-;$.$6$N@FD)6>:"Q@LG$CA=
MDUKHTJ-%F-6@&@G>$08%%B\R+%J7@$=&YD]G!&-(N"=F*5R(/1=Z0DV1QD0=
M@3T!*L1],UE7DS&+B40&XU?TR.%ASM-QP;+:*HNQV5R)>1]E6?:$S'*H3!XQ
M>Z'OQM'R1Z;S(RKERB1RNZ"'V9_#(&EC; YXJ0=Z^:9D]D$6'ICNG7D?OE$9
M("H#Y-4S0'*V=)PP&WYW 7NX^!+&XS$H-+)Q9\.T*QBI*(73.^#ECI4F $R9
M(P4V/8Y\U\7E3/";[K79]741%#31?;6SR@WH-\FJ(-./TBWDXBI'QPOC5:FR
MHB@XQ3R(L4FB1::-!8&S4*@NFX$A\Z[:FE@K]"(TAD 8.6-R': ': V1@3,&
M]H-:A.^AE7?UC)G3NT='J;$0 B G?8^7M\ =E,LAIQ[,",Q+A*EA,A#-X.0.
MP<K@WB#OD.W(M (?)[(_ A!Q[]8)?$^D2.89^+L#ZQ:C "XNTLB5&3\.V)@'
M / 1)7$L7B^1'G;.8N('SS7P+:,WN'H&1$LD]*+E<?+G-1:"D>#TP6"@^1S(
M/ E\F&)$O3@ MX/NG*38B.O@,X*8]\ASQ;P*+5D1W,B87V@Z]K-[UN^OD6??
M0,X^)@G6VH'K*/![W+K1V.6P?+RF^;/J_)]=6_MKR"X#CM%&3R3]'9U<%-@2
MD'JE"]+/YI:#N9,ARLRA>8L:VY;S%,1ZY,AY/C)O\%M:8/? R,*5R(E<31>N
M!],+CT+3.V%V-7X35AIG S";N\SXX'*3#-^K9:?=FZ*G??"(+ LPT(]=,FC$
M8HZ(]DTTJ^F2,9/$_C!U!4QEN8! V:AIKD@X.SLQR,5[4E_C%6PVF^0:F ZM
MGXY\7%AQ'LYZ)6V>OJLL]?@69)E\/CWOG!^==L[8U],O7\_@7_=:)?D]$[D/
M)VM.;.Z XRJ'%PW#I2E*\ZF="_(W0<@)W\CQLOE]"W+[IO8,/#WM4R[\,[U1
M;O\V>1O&RDOXRA+^)K+/ N&FOH-;*PM2%!\?NEYFLQ3S@,ZK$:Q>+=<?))A>
M*[=6'$&M46[,C6"%KL  NAEE)!<R4%9$E,&&"P\IM;%=ZCZ\$418CT=WG'OL
M7:,^%0=XUZS,#NO.CUU[,C@6CRDLP/3J;S-X>-?0R^VID5 OU31_T6G^>.;N
M<P3 ),]7FT9GO=Q:97K](P:\)FUJ$[B(=9'IY& I"\1\D!\69 XHF/PR3,C!
MP%_XG[%S:[I".$5+86 T,Z(H"P-K:6M^G[VK5C(@@>:GP"#DBF&4:]E;CKDE
M.Z!GA=FM&0C#B%+''@-ZVJ&%/7O:-, (:"26[I*UW;%Y3Q$3_\X3VU'2K'8%
MVO6 ]NFI.4F8:\$VI.F]0@ '7%,F!(&NY"7@+B7+((!3)8@H=! EB(%PRMF#
MYN2V-8=2J.!%:-B@Q^!E=SS0"C]I>;#Z*2>'<I1198(_7R(<IH^7? ],(L"V
MX^.>*!@EWISNENH[ ;PB[:DWF39Z9G)Q$=F3">^N.?W(!.OBF2J,4>S^@TY@
M H,%SF<DEBJ(;D <^;BV</%\^8PS21PL$BYD0U#DHT=F!XB#QH3FA4V"(+#1
M<MM$U'XS ["ZJ@F#[S"+;RZ793:B*[5XNSQMSDV[KWA+>V*A;0C=-]AIO;@\
MN>IT3\^_**=U71+_(A&;CPCZ%/F9+/ 1YQ&@'_IE"VV_8JYE (] Y^QLE-7F
MF-"W.%LH634/2=@'#O<HD!.8=PR719$WH4:"<"RDIDG[D[F;KB#R(F=Z'1.'
MIOS\E+0S/ DI7D!ZA/82B'UF:.IEP^1]$Z39A+2"/V2JI:E]&Q+45/E4*I]*
MY5,]K&B?6%%'J=GGJ-E3[TE*5FZ2T]@_N..RRZD=6UIF3S#X+JX9>]80E.GV
M[Z/+54LZX*F!53]D__1!XI:S'J[E#SQHR9X$UV?V0Y/;YUCDAXK-0Z@0)QM"
M0G$;,9.BPZ@KW]4UHU(1T9E*N;HDR(>75PF+8\@O'">9;QNB?O/@8X9OPJ+)
MK,HC7WSAXB/+0N?G0YM3 1%'0\<S<5<_6+2:0(;&NG%P@SO?+WD0"UL3;G.Y
M3!0(!F P_4^N1=(Z)KG=DSU#*5 FZ,CN]**4A&1^8R[\]L_K7!,/Q(*N$V3F
M!_PZH.5;Y4N^J)+K3E4;6N3)/5!]*!-3M)TP<3=$8!'[?!S$ ]9!1]"2DRLI
MLW%^W G3*AIJ1_DOSQ@408J$OT3"SK_.OR_.S"]N&.)ZLM7AM=&UN"S3UJ)K
MROY?F/PO=NR+E3N3N;[8HY<*6$RQG]Y68$Q5>*M.UJ*3_9,%!FXV@U1LP0DG
MT3"XAOJ'@ON>'U%BJ=C(@ [ ] H66(]HT8DOA>+#79*F)5=_Y-Y+W'J.!9V2
M2DV3/22BT(<HPI!$[LIJ-OVZND,C@V;$+<<=R90Y(:V,.QYPXNR454*UB<P^
MCXBKH3(F7]R8?$)M*<R"BVD+N0F"RPK\G@,='U!5 '+')[5UPS2M.(QB^QX;
M^\R#  S1R_O 'V-9@2$FQ1TY9*&F-N;GRZ,I$_.K/^+@%O;CD*0DBEG+\@-;
MYJF"^?OYN,,&L4/?T.9FZ7PNM(M/J3B(,TC\T-3@3=Y_>GZ<OM^<&,%ES/AW
M':Q-$=Q/BJ1A+0M\3888]X]1 O"'C28U-J@4ER@')%>/7><&504).5SXP3M@
MD)G"L536(?5HL^.%[F>[+8HOR+PV40PBL[DF3;ZEI7W;H3JS8DM-Z,<!5L/&
MC!C!],)J)9PS:7&\$F[XBEU!W#L_N)%YG)=#S/<R!(L+'!3*E#&:KB^!NA9W
M%62K8 GZS83X0 #,3WQ4TT/?M54>TDNG4D\5C)%37>8-H2Q! 90FZDA!E%C"
M?1\K6\RJB\1PBT-I?F7+GKFF"+LBDZ&5CA6#Z/_*H0'VV73<1/[@8C8MB;H<
M<#%;<=#FHDJ0, K!>ALFFQ!D2-<)4XDZ8Q@BXE"HX<TSQ:CRG;0*UNNP:4@3
MY\G7)V?YQ<#((/+]&X(JP-GB(AE/V,BF6+%*JK*D=6&FCCW8BMIDLWLJ4^OF
MCW3_Q!4GLP9$_V=0NDROE/Y(UVPFNRQD2N'RK&\4&;)J+@BV?DQESF3:C*BT
M-V<E+BBAB_X)/BE*G<Y7ADYLPA<H!%"E/R]"^\797D<7Y^#'GIP?G;"CSMD9
MZX"@_W'RZ:ASW67')]W.Z=E\\M?:>KJTQ/=BW%S2)GRP7($9E//JQ2+ER4%D
M^')/F2BDA*L/(68OO\#Q+(NEZMI9=0SPHT+5#TBQ%^S$$NWT#>P"\_Z!XN";
M23QL+'_BM:@+E0I8(R?=S2;8#]ZSS# 2E='SW/Z/9[(E&@(41!ELP=_?UIJ'
M\KRES:;B&:Y\GL<X4?)'WUZKU7K/&HU*J5&M-1E1D7ZPO=/LBOQ[IK.]MM%^
MCR4T2XUZN[;91 ;CP#7O-XC,E<I[UFQ62D:E6GF$S(U:\SVK-HQ26V^WU]/M
MQT_06!8]Z."6-B1M6@#R%CPSVBETZYBD7^4-'M%>A)B$X$A/OYKLWJ@M/2!@
MH^#4H<WQ8 C:&Z Q:NU:K:%75&ZMRJU5N;6OD%N;D\RY'L.DX$&8O\"A<D\S
M)9>TV1I'0X?WV<E/;L64VG6!I4%(];8/Z89+,P9OWOIB!@&X"M?_NM3DP9D\
M\WQ';,+#X(QL8+/U D8>S"A_#AV+B"J%PON+"E(]?/K/PK#3U+D_M'$EK>,S
M.04(MY)R&W=X_O'[VVKKL+-9E0Z7:/,>%@^?I=*&1KYH0_:F'S^52=.F"IK,
M\3S_E@P.6;<3X_FB!VF%:.["Y4!N1$Y.3D#T36U=2[JM9:K.3VUGVR,K1<0_
ML8ZY?X<]?R]7*EWJ+N+6=<W P7,ALM5;9>0O6%R_=6$Y>?:$VK*FY=C42 ]8
M&?1\.KI@JO?(C$EO$JXL3EG+5CFA3<KI2K&?X3M5FYG>_#<:B8*J*=<RU6AH
MZ3G%AEPL%E.:EJY]N(W*-*&)+WEV#V,.;AU1G@#O<CP;@!8 <4 BBN)?CD?%
M+T5*Z:T#-N6#(8-:U5ACR$ L@]C *"'1#BB0+E)?%@03\EPB+3^U1/FKRU Z
M2/NS6%(KG?D^[:$GC%+.P2,=7&.=MT<)3#T_ @O>Q),FTAX+%),T$*LE(H@\
M B<6=\9&3H3KD*#?:H=R);'DRF%/&J'+24%BFCG<)+DK%Q'ZW$85C-(B#D39
M#M>\@UG]@XH@A[&%^STU\1IXM28:%!^Q^]DOT/G.?@Z'F,21_48>V)#]2M1T
MRWXS*74\=1^,>#3S79)Q-?W=S#LMTYOJY.QUN=:;_0J7?*<^)Z?.37T9H*2;
MZCGP@6-(8?HV*OR4_8I.VYKJ S(N70^._.PEL5$%6=XGNU9<2NI0\8%09^GI
M2[C*+,\O"1W J1E@H@PB"'61A@]F(!; \X$MJTW0YFCB4)_N2T[D$!P2"6^B
M_F72TWF\D3I &P"T;0\SXU ]QX$ISE:21NF<D9.<_"(.Z\"UJLFY'P_7RR(M
MQN]!T^6T8JH+3Q?\B5<N'[F:6,DKKX9>OLR6?24*K<:[I6?&H! 090C0?#*Q
M]BBEE@D'1,!T\;&&TQ5* :I)DU1*/MTZ[WM)B2;:;B9='WG.]H,S9.H%XH$\
M^9R<?R4=O94.P2*C3YZH16,;<G><G@HSM^4UJ9(2#C&Y$$B:.>_3F2)$IH[!
MW#*]/)7^5\N&;B2.0673/L,YY&0.24(%L=Q6(-$N\I5Q+FB8UQ'S2354H<XI
MQ;-'T\,2SAT:_F0H+&\ZJ5:(;^B9TBG,V.*9>#V>YT,9[I2'14<%]X4=)"T@
M4C&/#T2\)AYCJ;1$D4D30E84!L4T&D]<-'PHC'O_I0JS/M4Z\Z$G@1/>B!OP
MC#DRTLA,VDL=/XW C,X[YMI&TKF ;T+TPB+L*-646A0!N3XY8GT'=_R&[S4\
ML(B2CC/$(MTFBMT"! )?YBQ/^FD-36\ 1.E849P)@I 9A'Q*:J"X]S 5T:L&
M2H"WN&14\@!7L -@.*;,;:=AR:/N:%2")N1086K*?9([)[:4B%.LP4K!E[#/
MIA7Y@31$0[&;#\>(0^H(K3Z?,_//-&>&2G6)/)FYHG0:9K80\FP>6H%#S"0#
M&<7Y2#P%[23["AV!52D% GHK%?WNIQMT\97 D_+\-))6E!RL:SJCD%KS>Z[,
MS";HRM.M87 /S080CWP<8?=E;V6B,SFX8("OO%V /$@1]!?GV;W9'+%$CN-;
M!G^WH)C4Z?F_3JZ[%U?LZN2LTSV].&='%^?=SE%W.J_@U7JYF)I?N4GFPU69
M?8V1W?GWBY0/!<Y%L/S(#\8^&4B=?M]T@G!IS'QSD$ICV#-JK?>L5C5*>K4Q
MGR24#V%/KWY_VP!)NC@2]*34L,=$Q?.7 Y^Q;J\;&*U)0_==4=#Q,T7N\QS!
MTN@2]O?MVWE)II:WU?*V6MY^B>7M1;-;%/M-)PNN_J!V<,UQR ^27P[!(,/<
MG@/'HP[00\]!4:M6-MHUA'<$\RBRDQ=+Y)<)^?N1/7^MWBPW:O6EERME_5G7
M#)C=SWORH<[J]7*MVG[Q9HURG:3DMI"@MEIG]PD+ @^ N'!L>G]_H[=2R;74
M;I%[/ Z,\4^F+S+5YP#ICU<782\Z2Z\NCO[YX^3LC'T[.3X]ZIQI[/0<?"!,
ML;_^_NGZ]/BT<W5Z,LFO+PI=P 4X/CF_/CE&9^#ZXNSTN-.%#Y\Z9QW<AW#]
M]>2DNTM4J:Q$E;UC%+P![DMFW:$?AUCA]?WC9*BN3H4*TB S.],V&FN@I- !
M.1%S:O//% V?2;H%P\9=9J\SZ-9*8W[,4-E]KF=#66KB/(N$4SMY?F&^%(IB
M^NN ;84VI#&/<4QHA('3Z]@LH<&KO2!GQJTF+O>^>V9L8P3^_5H!OS5<FWJ!
M!/%,( $-O#>YD$BUL4(;ORIY<C5RYL3MXOA0>L03_7(R.8AEZZV\%0GP;NE
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MV(K8,;_EKC\><2_*VPTI:-F8VG,+:&RI2"\HFW7-,(J97E0P1AM:NZ$.-"L
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M+FAT;5!+ 0(4 Q0    ( $TQ;E6C(M[X:@(  &L'   1              "
M =D5  !R;71I+3(P,C(Q,3$T+GAS9%!+ 0(4 Q0    ( $TQ;E4H 7G,;PH
M $E>   5              "  7(8  !R;71I+3(P,C(Q,3$T7VQA8BYX;6Q0
M2P$"% ,4    " !-,6Y5Z9O_<ZH&  #:,   %0              @ $4(P
M<FUT:2TR,#(R,3$Q-%]P<F4N>&UL4$L! A0#%     @ 33%N5:&.E9%;(0
M8<4! !X              ( !\2D  ')M=&EQ,S(P,C)E87)N:6YG<W!R+69I
=;F%L+FAT;5!+!08     !0 % % !  "(2P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
